Effects of chitosan oligosaccharide (COS) on the glycerol-induced acute renal failure in vitro and in vivo.
The purpose of this study was to investigate the effects of chitosanoligosaccharide (COS) on the change of inflammatory response, renal function factor, and renal oxidative stress in glycerol-induced ARF in vitro and in vivo. The molecular weight of COS was approximately below 10 kDa with 90% degree of deacetylation. Renal proximal tubular cells were treated with only COS (0, 0.01, 0.025, 0.05, 0.075 and 0.1%) or COS in the presence of glycerol (4mM). And rats were administered with glycerol (50%, 8 ml/kg) by intramuscular injection for the induction of ARF. For identification the protection effect of COS in the glycerol-induced ARF, rats were administered by COS (0.05 and 0.1%) using P.O. injection. The enzymatic activity of the released RDPase was assayed by the fluorometric method. The level of TNF-alpha in kidney or the culture medium was quantified using ELISA kit (R&D Systems, Minneapolis, USA) and, nitrite concentration was determined by the Griess reaction. We showed that COS stimulated the production of TNF-alpha, NO and the released RDPase. Glycerol increased the concentration of RDPase in kidney and decreased the released RDPase in proximal tubular cells. And, glycerol increased the production of NO, TNF-alpha, creatinine, and MDA, and decreased SOD. However, COS recovered the glycerol-induced inflammatory response, renal function factor, and antioxidant effect in kidney. COS had the antioxidant activity and the anti-inflammatory effect. And maybe that characteristics could help recover the glycerol-induced ARF.
College of Pharmacy, Research Institute of Drug Development, Chonnam National University, 300, Yongbong-dong, Buk-gu, Gwangju 500-757, Republic of Korea.
Hyun Joong
HJ
Yoon
Myoung E
ME
Moon
Haeng Soon
HS
Park
Hyun Woo
HW
Kim
Shun Young
SY
Im
Jun Haeng
JH
Lee
Young Ho
YH
Kim
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000517:prevention & control*; D000818:Animals; D048271:Chitosan / Q000494:pharmacology / Q000627:therapeutic use*; D004150:Dipeptidases / Q000378:metabolism; D005990:Glycerol / Q000037:antagonists & inhibitors* / Q000633:toxicity; D066298:In Vitro Techniques; D007687:Kidney Tubules, Proximal / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis; D009844:Oligosaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D012997:Solvents / Q000633:toxicity*; D013482:Superoxide Dismutase / Q000378:metabolism; D048069:Tumor Necrosis Factors / Q000378:metabolism
D009844:Oligosaccharides; D012997:Solvents; D048069:Tumor Necrosis Factors; D009569:Nitric Oxide; D048271:Chitosan; D013482:Superoxide Dismutase; D004150:Dipeptidases; C038937:dipeptidase; D005990:Glycerol